This page shows the latest Merck and Co/MSD news and features for those working in and with pharma, biotech and healthcare.
Combination treatment topped Pfizer's Sutent in phase 3. Merck &Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in ... According to Merck and Eisai, when administered alongside Lenvima,
The National Cancer Institute-sponsored GY004 study compared cediranib plus AZ and Merck &Co/MSD's leading PARP inhibitor Lynparza (olaparib) against chemo in patients with platinum-sensitive ovarian cancer, but ... and cervical cancer indications,
Its combination with Avastin is viewed as a central part of its strategy to gain ground on the leaders in the category, such as Merck &Co/MSD’s Keytruda (pembrolizumab) and ... Tecentriq has carved out a nice for itself in indications including
t have EGFR or ALK mutations, and is due to deliver a verdict by 15 May. ... If approved, BMS will finally have a regimen that can challenge its main rival in the PD-1 inhibitor category – Merck &Co/MSD and its Keytruda (pembrolizumab) product –
AZ/Merck look set to consolidate dominance in this indication. AstraZeneca and Merck &Co/MSD’s PARP inhibitor looks set to consolidate its grip on the ovarian cancer market, after being ... Lynparza has been the dominant drug in the PARP inhibitor
New treatment option for subset of patients with BRCA-mutations. AstraZeneca and partner Merck &Co/MSD can now add pancreatic cancer to the growing list of cancers targeted by their PARP ... The approval will help AZ and Merck to maintain a lead over
More from news
Approximately 0 fully matching, plus 54 partially matching documents found.
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
He takes over from Lilly’s John Lechleiter. Global pharma trade body the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has elected Merck KGaA's Stefan Oschmann as its new ... His pharma experience includes an 11-year
Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ... Oschmann also joined Merck in 2011, having spent the
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...